Repetitive intravenous dihydroergotamine as therapy for intractable migraine.
نویسنده
چکیده
For patients with chronic intractable headache, we compared a new treatment and a traditional one. Fifty-five patients (36 dependent on ergotamine, analgesics, diazepam, or corticosteroids) were given IV dihydroergotamine (DHE) and metoclopramide every 8 hours. Fifty-four age- and sex-matched patients (38 drug-dependent) were given diazepam intravenously every 8 hours. Forty-nine of the 55 DHE-treated patients became headache-free within 48 hours, and 39 of them sustained benefits in a mean follow-up of 16 months. In contrast, 7 diazepam-treated patients became free of headache within 3 to 6 days, and 31 had improved somewhat in 10 days. Repetitive IV DHE helps to terminate cycles of intractable migraine.
منابع مشابه
Inpatient management of migraine.
Migraine is a frequently disabling disorder which may require inpatient treatment. Admission criteria for migraine include intractable migraine, nausea and/or vomiting, severe disability, and dependence on opioids or barbiturates. The inpatient treatment of migraine is based on observational studies and expert opinion rather than placebo-controlled trials. Well-established inpatient treatments ...
متن کاملClinical Policy Bulletin: Migraine and Cluster Headache: Nonsurgical Management
Policy Aetna considers parenteral administration of dihydroergotamine (DHE) medically necessary for the treatment of intractable migraine or cluster headache. Prolonged multi-day administration of DHE is considered medically necessary when both of the following conditions are met: 1. Member has intractable cluster headache or severe migraine headache (i.e., status migrainosus, chronic daily hea...
متن کاملTreatment of acute migraine headache.
Migraine headache is a common and potentially debilitating disorder often treated by family physicians. Before diagnosing migraine, serious intracranial pathology must be ruled out. Treating acute migraine is challenging because of substantial rates of nonresponse to medications and difficulty in predicting individual response to a specific agent or dose. Data comparing different drug classes a...
متن کاملIntravenous dihydroergotamine for inpatient management of refractory primary headaches.
OBJECTIVE To determine dosing and side effects of dihydroergotamine as they affect outcomes in primary headache disorders. METHODS We audited our use of dihydroergotamine for inpatient management of disabling primary headache, focusing on the commonly treated problems. RESULTS Of patients interviewed, 114 had chronic migraine, 38 had cluster headache, and 11 had new daily persistent headach...
متن کاملA rational approach to the management of chronic migraine.
About 2% of the adult population has chronic migraine with only 20% diagnosed with this disorder. Those with medication overuse may improve with withdrawal of overuse medications. The intravenous dihydroergotamine regimen usually produces short-term benefit for those with medically refractory chronic migraine. OnabotulinumtoxinA and topiramate have shown efficacy in large placebo-controlled ran...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Neurology
دوره 36 7 شماره
صفحات -
تاریخ انتشار 1986